AA
ABVX

AlphaCentric Advisors’s Abivax ABVX Stock Holding History

AlphaCentric Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$381K Buy
+3,424
New +$405K 0.38% 91
2024
Q1 		– Sell
-267,500
Closed -$2.86M – 229
2023
Q4 		$2.86M Buy
+267,500
New +$2.73M 1.92% 12

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

AlphaCentric Advisors's ABVX Position: Q1 2026 in Review

AlphaCentric Advisors opened a new position in Abivax (ABVX) in Q1 2026: 3,424 shares worth $381K. The stake represents 0.38% of the portfolio and ranks #91 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in ABVX as recently as Q4 2023.

AlphaCentric Advisors first reported a position in ABVX in Q4 2023 and has held it in 2 quarters since. The position peaked at $2.86M in Q4 2023. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • AlphaCentric Advisors held 3,424 shares of Abivax worth $381K as of Q1 2026.
  • Abivax was a new AlphaCentric Advisors position in Q1 2026.
  • Abivax made up 0.38% of AlphaCentric Advisors's portfolio in Q1 2026, its #91 holding.
  • AlphaCentric Advisors first reported a position in Abivax in Q4 2023 and has held it in 2 quarters since.
  • AlphaCentric Advisors's Abivax position peaked at $2.86M in Q4 2023.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.